1. Home
  2. NBIX vs ELAN Comparison

NBIX vs ELAN Comparison

Compare NBIX & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$128.58

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Logo Elanco Animal Health Incorporated

ELAN

Elanco Animal Health Incorporated

HOLD

Current Price

$22.99

Market Cap

12.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBIX
ELAN
Founded
1992
1954
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
12.7B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
NBIX
ELAN
Price
$128.58
$22.99
Analyst Decision
Strong Buy
Buy
Analyst Count
22
9
Target Price
$180.36
$27.63
AVG Volume (30 Days)
906.6K
5.3M
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
41.95
N/A
EPS
4.67
N/A
Revenue
$161,626,000.00
$4,715,000,000.00
Revenue This Year
$22.85
$8.21
Revenue Next Year
$10.36
$5.29
P/E Ratio
$28.21
N/A
Revenue Growth
977.51
6.22
52 Week Low
$92.32
$8.02
52 Week High
$160.18
$27.72

Technical Indicators

Market Signals
Indicator
NBIX
ELAN
Relative Strength Index (RSI) 45.23 43.74
Support Level $124.09 $22.17
Resistance Level $136.74 $25.65
Average True Range (ATR) 4.22 1.02
MACD 0.16 -0.07
Stochastic Oscillator 40.54 25.84

Price Performance

Historical Comparison
NBIX
ELAN

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About ELAN Elanco Animal Health Incorporated

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Share on Social Networks: